Language / Ngôn ngữ:
McKaizer Institute — Longevity & Wellness Science
The race to defeat aging has never been better funded. This guide covers the most important longevity clinical trials underway in 2025 — from rapamycin PEARL trials to epigenetic reprogramming and senolytics.
$4.2 billion
invested in longevity biotech companies in 2024 alone — signaling that extending human healthspan is now mainstream science
Table of Contents
- Why 2025 Is the Most Exciting Year in Longevity Science
- The TAME Trial — Can Metformin Officially Slow Aging?
- Senolytics in Human Trials — Current Results and What Comes Next
- Epigenetic Reprogramming Trials — From Mice to Humans
- Rapamycin, Acarbose and mTOR Trials in Humans
- How to Participate in Longevity Research
- Monitoring Trial Outcomes — Key Endpoints to Follow
- The Next 5 Years in Aging Science
- Frequently Asked Questions (20)
Why 2025 Is the Most Exciting Year in Longevity Science

The TAME Trial — Can Metformin Officially Slow Aging?

“We are in the golden age of aging research. The trials running today will give us the data to add 10, 20, maybe 30 healthy years to the average human lifespan within this generation.”
Senolytics in Human Trials — Current Results and What Comes Next

Epigenetic Reprogramming Trials — From Mice to Humans

Rapamycin, Acarbose and mTOR Trials in Humans

How to Participate in Longevity Research

Monitoring Trial Outcomes — Key Endpoints to Follow

The Next 5 Years in Aging Science

✦ McKaizer Institute Protocol
Evidence-ranked, actionable steps distilled from the research above.
- Step 1: See the detailed protocol section above.
- Step 2: See the detailed protocol section above.
- Step 3: See the detailed protocol section above.
- Step 4: See the detailed protocol section above.
- Step 5: See the detailed protocol section above.









Leave A Comment